For the quarter ending 2025-09-30, AURX had $198,443 increase in cash & cash equivalents over the period. -$706,516 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -537,919 | -1,395,817 |
| Depreciation expense | 23,148 | 38,403 |
| Stock-based compensation | 19,915 | 42,544 |
| Provision for credit losses | 28,876 | 12,525 |
| Provision for inventory obsolescence | 0 | 9,119 |
| Vendor expense settled in shares of common stock | 18,000 | 15,000 |
| Amortization of operating lease right of use assets | 18,073 | 34,905 |
| Accounts receivable, net | 360,688 | 84,760 |
| Inventory, net | 35,811 | 24,493 |
| Prepaid expenses and other current assets | 43,307 | -108,515 |
| Accounts payable | 178,775 | 93,694 |
| Accrued expenses | 76,338 | 22,154 |
| Deferred revenue | -75,000 | 1,425,000 |
| Operating lease liabilities | -16,916 | -32,598 |
| Net cash used in operating activities | -706,516 | 264,191 |
| Purchases of property and equipment | 0 | 231,551 |
| Net cash used in investing activities | 0 | -231,551 |
| Net proceeds from issuance of common stock | 791,418 | 0 |
| Net proceeds from option exercises | 113,541 | - |
| Net proceeds from warrant exercise | 0 | 0 |
| Net cash provided by financing activities | 904,959 | 0 |
| Net increase (decrease) in cash | 198,443 | 32,640 |
| Cash and cash equivalents at beginning of period | 283,714 | - |
| Cash and cash equivalents at end of period | 514,797 | - |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)